Redica Systems
  • Login
  • Request a Demo
  • Products
    • Regulatory Intelligence
    • Inspection Intelligence
    • Site Intelligence
  • Solutions
    • Redica Systems Pharma Intelligence
    • Redica Systems MedTech Intelligence
  • Data & Services
    • Redica App
    • Catalyst
  • Company
    • About Us
    • People
    • Careers
    • Press
  • Resources
    • Blog
    • Assessments
    • Reports
    • Webinars
    • Glossary
Redica Systems
    • Regulatory Intelligence
    • Inspection Intelligence
    • Site Intelligence
    • Redica Systems Pharma Intelligence
    • Redica Systems MedTech Intelligence
    • Redica App
    • Catalyst
    • About Us
    • People
    • Careers
    • Press
    • Blog
    • Assessments
    • Reports
    • Webinars
    • Glossary
  • Login
  • Request a Demo

Resources

3 FDA 483 Stories in the Last 3 Weeks – Gilead, Alexion, and Novartis

Now I know why we’ve been getting more calls/emails from financial institutions and hedge funds inquiring about FDA 483s – more and more investors are being introduced to the term during investor calls. While technical in nature, digging through a company’s history of 483s – especially when compared to competitor company’s profiles – can uncover […]

Funding Cutbacks at FDA: A Sequester Primer

At a time when FDA’s responsibilities continue to grow rapidly, the agency has been caught in an across-the-board reduction (sequester) in federal discretionary spending, effective March 2, 2013. Although Congress may yet reverse course and restore money to affected federal agencies, this is not considered a high probability. Altogether, FDA will lose about $209 million […]

The State of the FDA—February 2013

FDA is the only federal agency that touches the lives ofeveryAmericanseveraltimeseveryday. Despite this, FDA will probably not be mentioned when President Obama delivers his State of the Union (SOTU) address to Congress on February 12. Instead, FDA Matters provides its third annual “State of the FDA.” As reflected in last week’s column, I think that FDA did well […]

FDA 483s – THIS MAY SURPRISE YOU

Just like great football coaches watch film of opposing teams, we have to watch what the FDA is doing – learn their tendencies and habits. One of the best ways to do that is through our film – the FDA 483. Need a quick refresh? Here’s a great list of 20 web-based (mostly free) resources […]

FDA conducted 40,000+ inspections in 2012

Actually, 41,129 to be exact. That’s almost 5 inspections per hour for the entire year of 2012. Based on new data that we obtained from the FDA, here are some other interesting statistics: 2 inspections in Bangladesh 1 inspection in Botswana 223 inspections in China  241 inspections in India 1 inspection in Guantanamo Bay 16 […]

20 Resources to Ace Your Next FDA Inspection

FDA inspections.  If you find yourself googling FDA inspector names, if you see your boss’s new Porsche parked in the parking lot with a license plate that says, “Zero 483s” (true story), then part of your job includes preparing your facility to be ready at any second for an FDA inspection. This post is for you.  Here are […]

4 Trends on The Rise of the FDA 483

byTony Chen I believe that FDA 483s are becoming increasingly important in our industry. Now that we’ve been in this particular space for almost 4 years, I’ve noticed some key trends. More interest from hedge funds. That’s right – we are actually getting contacted more and more frequently by hedge funds, investment banks, and others […]

New FDA 483s Video

If your job involves preparing for FDA inspections, watch this video and tell us what you think! Learn more about how FDAzilla can help you achieve your quality and inspection preparation goals: get 483s, Inspector Profiles, Enforcement Analytics, and GMP Regulatory Intelligence.

FDA After the Election—Part 2: Leadership and Change

For part 1 of this series regarding budget, click here. Apart from an occasional reference, FDA is not part of the campaign dialogue leading up to the November 6 nationwide U.S. election. Yet, FDA Matters believes that FDA will be strongly impacted by the election’s outcomes. Part 1 of “FDA After the Election” concentrated on the agency’s budget situation. […]

FDA After the Election—Part 1: Budget

Apart from an occasional reference, FDA is not part of the campaign dialogue leading up to the November 6 nationwide U.S. election.FDA Mattersbelieves this is probably good—any intelligentdiscussion of FDA’s future requires a long-term perspective and a mastery of detail and nuance—both of which are in short supply during “sound bite”-oriented politicking. Yet, FDA will […]
« Older Entries
Newer Entries »
Company
  • About Redica Systems
  • People
  • Careers
  • Press
  • Contact Us
Catalyst
  • Redica Catalyst
  • Redica ID
  • Enrichment
  • Knowledge Graph
  • Redica Ontologies
Use Cases
  • For Pharma
  • For MedTech
  • Inspection Preparation
  • Vendor Quality
  • Regulatory Surveillance
Resources
  • Assessments
  • Reports
  • Webinars
  • Document Store
  • Blog
  • Glossary

© 2026 Redica. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
  • Status